To everything there is a season: COVID-19 vaccination and thrombosis

[1] European Medicines Agency. Vaxzervia summary of product characteristics. 2021. Available at: https://www.ema.europa. eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf (Accessed: 07 May 2021).

[2] European Medicines Agency. COVID-19 vaccine safety update – VAXZEVRIA, 14 April 2021. 2021. Available at: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-april-2021_en.pdf (Accessed: 07 May 2021)

[3] Skajaa N, Horváth-Puhó E, Adelborg K, Prandoni P, Rothman KJ, Sørensen HT. Venous thromboembolism in Denmark: seasonality in occurrence and mortality. TH Open. 2019; 3: e171–e179.

[4] Ferro JM, Lopes GC, Rosas MJ, Araújo C, Henriques I, Venoport Investigators. Chronobiology of cerebral vein and dural sinus thrombosis. Cerebrovascular Diseases. 2002; 14: 265.

[5] Vannini L, Llanos Gómez JM, Quijada-Fumero A, Fernández Pérez AB, Hernández Afonso JS. COVID-19 quarantine and acute pulmonary embolism. Revista Española de Cardiología. 2020; 73: 680–682.

[6] Franch-Llasat D, Mayor-Vázquez E, Pedregosa-Díaz J, Herrero-Redondo M, Ortin-Font X, Roche-Campo F. e-Thrombosis in the COVID-19 era: collateral effects of confinement. Medicina Intensiva. 2021; 45: 122–124.

[7] Koudouovoh-Tripp P, Hüfner K, Egeter J, Kandler C, Giesinger JM, Sopper S, et al. Stress enhances proinflammatory platelet activity: the impact of acute and chronic mental stress. Journal of Neuroimmune Pharmacology. 2021; 16: 500–512.

[8] Sandrini L, Ieraci A, Amadio P, Zarà M, Barbieri SS. Impact of acute and chronic stress on thrombosis in healthy individuals and cardiovascular disease patients. International Journal of Molecular Sciences. 2020; 21: 7818.